Resum
Background
Cytokines, such as interleukins (IL)-4/5/13, play a key role in multiple type 2 inflammatory diseases, including allergic asthma. Dupilumab, a human monoclonal antibody, blocks the shared receptor component for IL-4/IL-13, inhibiting signaling. In this post hoc analysis of VOYAGE (NCT02948959), dupilumab efficacy was evaluated in patients aged 6–11 years with type 2 asthma with or without evidence of allergic asthma (baseline serum total IgE ≥30IU/mL and ≥1 perennial aeroallergen-specific IgE ≥0.35kU/L).
Methods
Annualized rate of severe exacerbations (AER) and changes in pre-bronchodilator (Pre-BD) forced expiratory volume in one second (FEV1), percent-predicted pre-BD FEV1 (ppFEV1), and Asthma Control Score (ACQ)-7 were assessed during the treatment period.
Results
350 children (261 with and 89 without evidence of allergic asthma) were included. Dupilumab vs placebo significantly reduced AER in patients with (0.24 vs 0.62, relative risk reduction[RRR]: 62% [95% CI, 39–76], p
Conclusion
Dupilumab vs placebo reduced asthma exacerbations in children with type 2 asthma irrespective of evidence of allergic asthma; similar trends were observed in changes in lung function. Significant improvement in asthma control was observed in patients with evidence of allergic asthma, but not in those without.
Cytokines, such as interleukins (IL)-4/5/13, play a key role in multiple type 2 inflammatory diseases, including allergic asthma. Dupilumab, a human monoclonal antibody, blocks the shared receptor component for IL-4/IL-13, inhibiting signaling. In this post hoc analysis of VOYAGE (NCT02948959), dupilumab efficacy was evaluated in patients aged 6–11 years with type 2 asthma with or without evidence of allergic asthma (baseline serum total IgE ≥30IU/mL and ≥1 perennial aeroallergen-specific IgE ≥0.35kU/L).
Methods
Annualized rate of severe exacerbations (AER) and changes in pre-bronchodilator (Pre-BD) forced expiratory volume in one second (FEV1), percent-predicted pre-BD FEV1 (ppFEV1), and Asthma Control Score (ACQ)-7 were assessed during the treatment period.
Results
350 children (261 with and 89 without evidence of allergic asthma) were included. Dupilumab vs placebo significantly reduced AER in patients with (0.24 vs 0.62, relative risk reduction[RRR]: 62% [95% CI, 39–76], p
Conclusion
Dupilumab vs placebo reduced asthma exacerbations in children with type 2 asthma irrespective of evidence of allergic asthma; similar trends were observed in changes in lung function. Significant improvement in asthma control was observed in patients with evidence of allergic asthma, but not in those without.
Idioma original | Anglès |
---|---|
Pàgines (de-a) | 2157-2167 |
Nombre de pàgines | 11 |
Revista | Allergy: European Journal of Allergy and Clinical Immunology |
Volum | 78 |
Número | 8 |
DOIs | |
Estat de la publicació | Publicada - d’ag. 2023 |